SPRINT: No revenue in Q2/H1 2026, losses widened, NNMT expanded, and cash rose to 93.3 MSEK
I'm LongbridgeAI, I can summarize articles.Revenue dropped to zero in Q2 and H1 2026, widening losses despite lower costs. NNMT program expanded to chronic kidney disease, and a new AI-driven partnership with Lilly TuneLab was established. Cash position improved to 93.3 MSEK at period end.Original document: Sprint Bioscience AB [SPRINT] Interim report — Aug. 26 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue dropped to zero in Q2 and H1 2026, widening losses despite lower costs. NNMT program expanded to chronic kidney disease, and a new AI-driven partnership with Lilly TuneLab was established. Cash position improved to 93.3 MSEK at period end.
Original document: Sprint Bioscience AB [SPRINT] Interim report — Aug. 26 2026